Vitamin C: Clinical Trials

Department of Health and Social Care written question – answered on 23rd February 2021.

Alert me about debates like this

Photo of James Wild James Wild Conservative, North West Norfolk

To ask the Secretary of State for Health and Social Care, when the REMAP-CAP clinical trial on Vitamin C will conclude.

Photo of Jo Churchill Jo Churchill The Parliamentary Under-Secretary for Health and Social Care

REMAP-CAP is an adaptive trial and results are monitored on an ongoing basis. A Statistical Analysis Committee (SAC) regularly evaluates the trial data to determine whether a pre-specified threshold for statistical significance or statistical trigger is reached. If a statistical trigger has occurred, it is communicated immediately to the trial Data Safety and Monitoring Board (DSMB).

The DSMB is responsible for determining whether a statistical trigger should lead to conclusion of a trial arm. The DSMB is also responsible for ensuring treatments that are clearly ineffective will be discontinued promptly. The DSMB have not yet reported any statistical triggers or safety concerns for vitamin C in REMAP-CAP and the Principle Investigators of REMAP-CAP and Department are blinded from SAC evaluations.

Conclusion will be dependent on recruitment to REMAP-CAP and the strength of any therapeutic effect of vitamin C.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.